FDA Determines Regulatory Review Period for OPDUALAG Patent Extension

Summary

The Food and Drug Administration (FDA) has published a notice determining the regulatory review period for OPDUALAG's patent extension application, submitted to the US Patent and Trademark Office (USPTO) for a human biological product patent.